Background: The study aimed to compare the effect of lipid lowering with Atorvastatin and Rosuvastatin in diabetic dyslipidaemic patients and the assessment of cognitive impairment using AMTS scale.
Meterial and Methods: The study was conducted in a hospital at Elayampalayam for 6 months period in patients with Diabetic Dyslipidemia and having Atorvastatin or Rosuvastatin from 6 months to 3 years were included in the study. The data obtained was introduced to compare the most effective lipid lowering statin and to assess the cognitive impairment induced by both statins. To determine the significant difference between the reduction of lipid parameters, statistical test (Student t test) was introduced.
Results: A total of 86 patients were included in the study in which 62.8% accounts for males and 37.2% accounts for females, and most of the patients were in the age group of 61–70 years. Greater percentage reduction of TC, TG and LDL-C level was seen in 3 years history patients and it was found to be 25.01%, 29.6%, 38.5% with Rosuvastatin and 22.7%, 25.6%, 36.6% with Atorvastatin. In the total study population it was found to be 23.4%, 25.4%, 34.2% with Rosuvastatin and 19.8%, 20.1%, 30.6% with Atorvastatin. Rosuvastatin showed only 27.9% moderate impairment and no severe impairment but Atorvastatin showed 58.1% moderate impairment and 6.9% severe impairment in Diabetic Dyslipidaemic patients.
Conclusion: Rosuvastatin was found to be more effective in Diabetic Dyslipidaemic patients and showed only a less Cognitive impairment than Atorvastatin.